Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal CarcinomaYuan Zhang, Jun Ma, Zhibin Cheng et al.|New England Journal of Medicine|2019Cited by 934
Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trialYu‐Pei Chen, Jun Ma, Xu Liu et al.|The Lancet|2021Cited by 234
Final Overall Survival Analysis of Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma: A Multicenter, Randomized Phase III TrialYuan Zhang, Ling‐Long Tang, Lei Chen et al.|Journal of Clinical Oncology|2022Cited by 147
Unraveling tumour microenvironment heterogeneity in nasopharyngeal carcinoma identifies biologically distinct immune subtypes predicting prognosis and immunotherapy responsesYu‐Pei Chen, Jun Ma, Jia‐Wei Lv et al.|Molecular Cancer|2021Cited by 99
Medial retropharyngeal nodal region sparing radiotherapy versus standard radiotherapy in patients with nasopharyngeal carcinoma: open label, non-inferiority, multicentre, randomised, phase 3 trialYan‐Ping Mao, Jun Ma, Shunxin Wang et al.|BMJ|2023Cited by 42